Claritas Pharmaceuticals Inc V.CLAS.H

GVHD Still Kalytera's !!!

[HighSkies2019]

Kly purchased Talent 2017 ....Kly is now Claritas ..so Talent is a subsidiary of Kly/Claritas....we got a nr saying we changed our name KLY to Claritas and it was a name change only... nothing changed as far as business operations or business plan ....If you check govt clinical trials and Google the NCT number listed below ....GVHD was updated Sept 1 2021 and the clinical trial is still active but not recruiting ....anticipated completion Nov 2022 and anticipated study date Dec 2022 ....I pulled this part from pub med site ..15 Mar 2021 Phase II trial is ongoing for Graft-versus-host disease (Prevention) in Israel and Australia (NCT03840512) (ACTRN12619000623190).... this is why I was leaning towards a buyout and the reason for delays across the board with everything publicized in NR such as.. clinical start date ..PAH lisence Salzman to Claritas confirmation and transfer of shares for transaction ...IND which in nr says awhile back they applied for.. getting their financials current on file ..Bob had nothing to do with Talent I felt that the GVHD delay was so Bob would get his piece of the pie ..the halt gave us AUD refund amount and mention of finance to cover phase 1 once authorized by TSXV .... the particulars of our GVHD and past Talent debt and recent sign off...hoping that both parties will be rewarded on the GVHD aspect ...or could it be possible big partner...the above questions could be the run out of NR expected to push price up ...then once phase 1 data released a buyer...but because of the results from nitric oxide already publicized to stop the viruses and mutations...and NO already FDA approved was thinking that because of the over powering Delta virus that we will be FDA accelerated...and already got a deal in place ...here's looking forward to what we see this week in NR...gltal